This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
SCD-HeFT, the Sudden Cardiac Death in Heart Failure Trial, was a completed randomized phase 3 clinical trial with a primary treatment purpose. The registry identifies amiodarone and implantable defibrillators as the trial interventions and lists arrhythmia, cardiovascular diseases, sudden cardiac death, heart diseases, congestive heart failure, and heart failure among the conditions studied.
| Feature | SCD-HeFT |
|---|---|
| Official title | Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) |
| Phase | Phase 3 |
| Status | Completed |
| Start date | 1997-05 |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Registry identifier | NCT00000609 |
2. Clinical Question
The registry identifies a treatment trial conducted in the setting of heart failure and related cardiovascular conditions. Its intervention field identifies both amiodarone, a drug intervention, and implantable defibrillators, a device intervention.
Population
The registry lists arrhythmia, cardiovascular diseases, sudden cardiac death, heart diseases, congestive heart failure, and heart failure as conditions associated with the study.
Intervention
Amiodarone is identified as a drug intervention, while implantable defibrillators are identified as a device intervention.
Study purpose
The primary purpose is listed as treatment.
Primary question
From a statistical-design perspective, the randomized treatment comparison is the central framework for evaluating the effects of the listed interventions on prespecified clinical outcomes.
3. Trial Design
Intervention structure
The registry identifies two intervention types: amiodarone as a drug and implantable defibrillators as a device. The registry information represented here does not specify the treatment schedules, doses, device programming, comparator details, or allocation ratio. Those design elements therefore cannot be characterized from the registry fields represented here.
Amiodarone
- Intervention type: drug
- Study role: randomized treatment intervention
- Registry-listed intervention: amiodarone
Implantable defibrillators
- Intervention type: device
- Study role: randomized treatment intervention
- Registry-listed intervention: implantable defibrillators
4. Endpoints
The ClinicalTrials.gov record represented here contains no registered primary endpoints. Consequently, the registry record does not provide an endpoint definition or time frame that can be reproduced as a registered primary endpoint on this page.
| Endpoint field | Registry status | Statistical implication |
|---|---|---|
| Registered primary endpoints | None listed | No registry-defined primary endpoint is available for endpoint-specific statistical reconstruction. |
| Endpoint definition | Not listed in the represented record | A specific event definition cannot be assigned from the registry fields available here. |
| Time frame | Not listed in the represented record | A specific analysis window cannot be assigned from the registry fields available here. |
5. Statistical Methodology
Randomized comparison
Randomization is the central design feature that supports causal comparison between assigned treatment strategies. Once treatment is randomized, the primary efficacy comparison is ordinarily based on the groups created by the randomization process rather than on post-randomization treatment selection.
The exact form of the treatment effect depends on the endpoint. It might be expressed as a risk difference, risk ratio, odds ratio, mean difference, rate ratio, hazard ratio, or another prespecified estimand.
Intention-to-treat principle
For a randomized treatment trial, an intention-to-treat analysis ordinarily compares participants according to their randomized assignment, regardless of subsequent adherence or treatment changes. This preserves the treatment contrast generated by randomization and avoids redefining the groups according to post-randomization behavior.
Endpoint-specific analysis
The appropriate statistical model depends on the endpoint definition. If the endpoint is a time-to-event outcome, Kaplan-Meier methods and a Cox proportional-hazards model are common approaches. If the endpoint is binary, a risk difference, risk ratio, odds ratio, or regression model may be appropriate. If the endpoint is continuous, a mean difference or regression-based comparison may be used.
Time-to-event endpoint
Typically requires explicit definitions for the event, censoring, time origin, and analysis population. Kaplan-Meier estimation and Cox regression are common methods.
Binary endpoint
Can be summarized with event proportions and compared using measures such as risk difference, risk ratio, or odds ratio.
Continuous endpoint
Can be compared using a difference in means or a regression model, with attention to the measurement scale and distribution.
Composite endpoint
Requires a precise definition of which component events qualify and how the first event or subsequent events are handled.
Confidence intervals
A confidence interval quantifies statistical uncertainty around an estimated treatment effect. It should be interpreted together with the effect estimate and the estimand being estimated. A narrow interval indicates greater statistical precision than a wide interval, all else being equal.
P-values
For a prespecified hypothesis test, a p-value describes the compatibility of the observed data with the null hypothesis under the specified statistical model. It is not a measure of the size of a treatment effect and does not describe the probability that the null hypothesis is true.
6. Planned Analysis
Because the ClinicalTrials.gov record represented here does not list registered primary endpoints and does not contain posted statistical analyses, the appropriate statistical interpretation is to describe how endpoints of different types would ordinarily be analyzed rather than assign an outcome to SCD-HeFT.
| Potential endpoint structure | Typical statistical analysis | Key considerations |
|---|---|---|
| Time to death or another clinical event | Kaplan-Meier estimation; log-rank comparison; Cox proportional-hazards model | Event definition, censoring, proportional-hazards assumption, follow-up, and analysis population |
| Binary clinical outcome | Comparison of proportions; risk difference or ratio; logistic regression when appropriate | Definition of the analysis window, missing outcomes, and prespecified covariate adjustment |
| Continuous clinical measurement | Mean difference or regression-based comparison | Measurement scale, distribution, baseline adjustment, and missing-data handling |
| Repeated measurements | Longitudinal or mixed-effects modeling | Within-participant correlation, timing of assessments, and missingness assumptions |
7. Statistical Methods Explained
Why does randomization matter statistically?
Randomization establishes treatment assignment independently of the patient's baseline characteristics, in expectation. This allows differences in outcomes between randomized groups to be interpreted as evidence about the assigned interventions, subject to the trial's adherence, follow-up, endpoint, and analysis assumptions.
Why is intention-to-treat analysis important?
Analyzing participants according to randomized assignment preserves the original comparison. If participants who discontinue, cross over, or otherwise deviate from their assigned treatment are selectively removed from an analysis, the resulting comparison can lose some of the protection provided by randomization.
Why would a time-to-event endpoint use Kaplan-Meier estimation?
Clinical trials often have incomplete follow-up because participants may remain event-free when observation ends. Kaplan-Meier estimation uses each participant's available follow-up while accounting for right censoring, rather than treating every participant without an observed event as if the event had never occurred.
Here, di represents events at time ti, while ni represents participants at risk immediately before that time.
What does a hazard ratio represent?
A hazard ratio compares instantaneous event rates between two groups under a time-to-event model. An HR below 1 indicates a lower modeled event hazard in the numerator group relative to the denominator group; it does not directly represent a percentage of patients who benefit or an absolute reduction in cumulative event probability.
Why is the confidence interval essential?
An effect estimate alone hides its statistical precision. The confidence interval shows a range of values compatible with the data and the specified model under the corresponding confidence procedure. Wider intervals generally indicate greater uncertainty than narrower intervals.
Why does the p-value not measure treatment benefit?
A p-value addresses evidence against a specified null hypothesis. A very small p-value can occur with a small effect when the sample is sufficiently informative, while a clinically important estimate can have a wide interval when information is limited. Effect size and precision therefore need to be examined separately from the p-value.
Why must the endpoint be defined before choosing the model?
The endpoint determines what quantity is being estimated. For example, time-to-event analysis explicitly incorporates follow-up duration and censoring, while a binary analysis reduces the outcome to whether an event occurred within a specified window. Using the wrong model can change the estimand rather than merely change the statistical technique.
8. Statistical Interpretation of a Randomized Drug-and-Device Trial
SCD-HeFT is statistically distinctive at the design level because the registry identifies both a drug intervention and a device intervention within a randomized phase 3 treatment trial. That combination makes careful definition of the treatment contrast especially important.
Drug intervention
Amiodarone is classified as a drug intervention. A statistical analysis of a drug strategy should preserve the randomized treatment assignment as the primary comparison.
Device intervention
Implantable defibrillators are classified as a device intervention. Device-based strategies can have procedural, follow-up, and exposure considerations that need to be represented explicitly in the endpoint and analysis definitions.
Multiple interventions
When a trial evaluates more than one intervention, the statistical interpretation depends on the exact randomized allocation structure and comparator definitions.
Clinical endpoint
The registry information represented here does not specify the primary endpoint definition, so the treatment effects cannot be assigned to a particular clinical outcome from this record alone.
9. Missing Statistical Specifications
Several design details that ordinarily determine the statistical analysis are not listed in the registry information represented here. Identifying these omissions is important because the statistical meaning of a trial result depends on the prespecified estimand and analysis plan.
| Statistical specification | Registry status in the represented record | Why it matters |
|---|---|---|
| Primary endpoint | No registered primary endpoints listed | Defines the principal treatment-effect estimand. |
| Endpoint time frame | Not listed | Determines the observation window and, for binary outcomes, which events count. |
| Sample size | Enrollment is not reported | Determines the amount of statistical information available for estimation and testing. |
| Allocation ratio | Not listed | Determines the expected distribution of participants across randomized groups. |
| Stratification factors | Not listed | Can determine the form of a stratified analysis and improve precision. |
| Multiplicity strategy | Not listed | Determines how multiple primary or secondary hypotheses are interpreted while controlling type I error. |
| Interim analyses | Not listed | Repeated looks at accumulating data require prespecified statistical control when used for confirmatory decisions. |
| Missing-data method | Not listed | Missing observations can affect both estimands and uncertainty. |
10. What Can Be Learned From the Registry Design
Even without posted endpoint results, the registry design supports several useful statistical observations. First, randomization establishes the framework for a comparative treatment analysis. Second, the trial is classified as phase 3 and has a treatment purpose, placing it within the confirmatory-development framework typically used for evaluating clinical interventions. Third, the study contains both drug and device interventions, making the precise definition of each randomized treatment strategy particularly important.
At the same time, the absence of registered primary endpoints in the represented record prevents an endpoint-specific assessment of statistical effect size, precision, or hypothesis testing. Those quantities require an explicitly defined outcome and analysis population.
A randomized design tells us how treatment groups were intended to be compared; it does not by itself establish whether one intervention changed a particular clinical outcome. That conclusion requires a prespecified endpoint, an analysis population, an appropriate estimator, and observed outcome data.
Two analyses can use the same randomized treatment groups yet answer different questions if they use different outcome definitions or time horizons. The endpoint therefore belongs to the estimand itself, not merely to the reporting section of a clinical-trial record.
Randomization improves causal interpretability, but it does not eliminate problems created by missing follow-up, treatment crossover, nonadherence, informative censoring, or inappropriate statistical modeling. These issues must be handled according to the prespecified analysis strategy.
11. Limitations
- No registered primary endpoints: the ClinicalTrials.gov record represented here does not list primary endpoints, so endpoint-specific treatment effects cannot be evaluated from the registry information.
- No posted statistical analyses: formal statistical analyses are not posted in the represented ClinicalTrials.gov record.
- No enrollment value: the enrollment field is not reported in the represented record, so the sample size cannot be characterized from that field.
- Limited design detail: the represented registry information does not specify the allocation ratio, treatment schedules, comparator details, stratification factors, interim-analysis plan, multiplicity strategy, or missing-data approach.
- Endpoint uncertainty: without a registered endpoint definition and time frame, a particular statistical estimand cannot be assigned to the trial from the registry fields represented here.
- Randomized design does not remove all bias: post-randomization events such as treatment changes, nonadherence, missing follow-up, and differential observation can affect particular estimands and analyses.
12. Why This Trial Matters Statistically
SCD-HeFT is a useful statistical teaching case because its registry design combines randomization, phase 3 treatment evaluation, and both drug and device interventions. The trial illustrates why the statistical analysis of a clinical trial begins with the treatment contrast and endpoint definition rather than with a statistical test selected after the data are observed.
| Concept | How it appears in SCD-HeFT |
|---|---|
| Randomization | The registry classifies the allocation as randomized. |
| Phase 3 design | The study is classified as phase 3. |
| Treatment purpose | The primary purpose is listed as treatment. |
| Drug intervention | Amiodarone is identified as a drug intervention. |
| Device intervention | Implantable defibrillators are identified as a device intervention. |
| Endpoint specification | No registered primary endpoints are listed in the represented record. |
| Statistical analysis | No posted statistical analyses are listed in the represented record. |
| Estimand definition | Requires a specific endpoint, time frame, treatment contrast, and analysis population. |
| Evidence interpretation | Requires separating randomized treatment assignment from post-randomization events and endpoint-specific analysis decisions. |
13. A Practical Statistical Framework for Reading SCD-HeFT
A rigorous reading of a randomized treatment trial can be organized into a sequence of questions. The first is what was randomized? The second is what population was analyzed? The third is what outcome was defined in advance? The fourth is over what time frame was the outcome measured? The fifth is what effect measure was estimated? Finally, the analyst should ask how uncertainty, missing observations, protocol deviations, and multiplicity were handled.
For SCD-HeFT, the first two questions can be answered at the registry-design level: the study was randomized, phase 3, and treatment-focused, with amiodarone and implantable defibrillators identified as interventions. The remaining questions require endpoint and analysis information that is not listed in the represented registry record.
14. Source Record
- ClinicalTrials.gov: SCD-HeFT, NCT00000609.
15. Record Summary
SCD-HeFT is a completed randomized phase 3 treatment trial sponsored by the National Heart, Lung, and Blood Institute, with amiodarone identified as a drug intervention and implantable defibrillators identified as a device intervention. The registry associates the study with arrhythmia, cardiovascular diseases, sudden cardiac death, heart diseases, congestive heart failure, and heart failure.
From a statistical perspective, the key feature that can be established from the registry is the randomized treatment design. The ClinicalTrials.gov record represented here does not list registered primary endpoints, does not provide an enrollment value, and contains no posted statistical analyses. Consequently, the central statistical lesson is methodological: the randomized treatment contrast must be connected to a precisely defined endpoint, time frame, estimand, analysis population, and uncertainty procedure before an effect can be interpreted.
Continue through the Clinical Biostats trial-analysis collection
Explore additional clinical-trial statistical analyses and the methods used to interpret randomized evidence.